Muutke küpsiste eelistusi

Gynecologic Cancers: An Expert Guide to Management in the Real World 1st ed. 2024 [Kõva köide]

Edited by , Edited by , Edited by
  • Formaat: Hardback, 490 pages, kõrgus x laius: 254x178 mm, Approx. 490 p., 1 Hardback
  • Ilmumisaeg: 13-Jun-2026
  • Kirjastus: Springer Verlag, Singapore
  • ISBN-10: 9811068496
  • ISBN-13: 9789811068492
Teised raamatud teemal:
  • Kõva köide
  • Hind: 116,69 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 155,59 €
  • Säästad 25%
  • See raamat ei ole veel ilmunud. Raamatu kohalejõudmiseks kulub orienteeruvalt 3-4 nädalat peale raamatu väljaandmist.
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
Gynecologic Cancers: An Expert Guide to Management in the Real World 1st ed. 2024
  • Formaat: Hardback, 490 pages, kõrgus x laius: 254x178 mm, Approx. 490 p., 1 Hardback
  • Ilmumisaeg: 13-Jun-2026
  • Kirjastus: Springer Verlag, Singapore
  • ISBN-10: 9811068496
  • ISBN-13: 9789811068492
Teised raamatud teemal:

This book presents expert viewpoints on the diverse situations faced by practitioners in their daily practice when caring for patients with gynecologic cancers. The aim is to equip readers with all the knowledge required in order to implement appropriate case-by-case approaches in the real world, where circumstances frequently differ from the typical or straightforward scenarios depicted in textbooks and articles. The presented situations cover every possible diagnosis that can be seen in the field of gynecologic oncology, and address all stages of disease. The approaches that are described also reflect variations in interpretations by experts according to their place of practice, the available medical infrastructure, the insurance system, economic and cultural circumstances, and the prevailing medical philosophy. The message is essentially that “one size does not fit all”! The book will serve as a superb reference for novices less familiar with the field, but it will also be a valuable aid for more experienced practitioners and will even offer assistance in research planning.

1. Prevention of Ovarian Cancer in Young Women with a Strong Family
History of Ovarian Cancer.- 2. Family History of Ovarian and Breast Cancer.-
3. Familial Breast/Ovarian Cancer.- 4. Familial Ovarian Cancer.- 5. Stage 1
High-Grade Fallopian Tube Cancer in a Young Woman.- 6. Vaginal Cancer: Stage
1 Bulky Squamous Cell Carcinoma.- 7. Recurrent Granulosa Cell Tumor of the
Ovary.- 8. Completely Resected Stage Granulosa Cell Tumor of the Ovary.-
9. Granulosa Cell Tumor: Emergency Surgery.- 10. Ovarian Fibrosarcoma in a
Young Woman.- 11. Vulvar Cancer: Stage Squamous Cell Carcinoma.- 12. Vulvar
Cancer: Malignant Melanoma.- 13. Vulvar Cancer: Stage .- 14. Vulvar Cancer:
Locally Advanced Disease.- 15. Gestational Trophoblastic Disease: Persistent
Mole.- 16. Apparent Stage Endodermal Sinus Tumor in a Woman Desiring to
Preserve Fertility.- 17. Ovarian Cancer: Germ-Cell Tumor (Yolk Sac).-
18. Recurrent Ovarian Dysgerminoma Confined to the Pelvis.- 19. Recurrent
Ovarian Germ-Cell Tumor (Endodermal Sinus Tumor) Following a Response to
Chemotherapy.- 20. Ovarian Cancer: Germ-Cell Tumors(Teratoma, Grade 2).-
21. Elevated CA-125 in a Premenopausal Woman with No Known Cancer.-
22. Elevated CA-125 in a Postmenopausal Woman.- 23. Metastatic Carcinoma,
Pelvic Mass With History of Colon Cancer.- 24. Metastatic Carcinoma.-
25. Primary Peritoneal Mesothelioma.- 26. Primary Peritoneal Carcinoma.-
27. Ovarian Cancer, Epithelial Tumor with Multiple Previous Therapies.-
28. Intraabdominal Cancer: Advanced Disease at Presentation.- 29. Ovarian
Cancer, Epithelial (Stage IA, Clear Cell).- 30. Ovarian Cancer, Epithelial
(Early Disease, Unstaged).- 31. Progressive Cervical Cancer in a Patient Who
Wants Everything Done.- 32. Abnormal Radiolabeled Antibody Scan in an
Ovarian Cancer Patient.- 33. Recurrent Ovarian Cancer 4 Years AfterInitial
Diagnosis.- 34. Stage IIC Ovarian Cancer Which Is Completely Resected.-
35. Recurrent Ovarian Carcinoma: Bowel Obstruction.- 36. Bulky Stage Ovarian
Cancer with Excellent Response to Chemotherapy.- 37. Second-Look Laparotomy
in an Ovarian Cancer Patient Responding to Chemotherapy.- 38. Secondary
Surgical Cytoreduction in a Patient Responding to Chemotherapy.- 39. Advanced
Borderline Tumor of the Ovary.- 40. Microscopic Residual Ovarian Cancer at
Second-Look Laparotomy.- 41. Stage Mixed Mesodermal Cancer of the Uterus.-
42. Stage Endometrial Cancer with Positive Washings.- 43. Papillary Serous
Adenocarcinoma in an Endometrial Polyp.- 44. Uterine Cancer, Stage IC, Grade
3.- 45. Uterine Cancer: Adenocarcinoma Stage .- 46. Uterine Cancer, Stage ,
Grade 3 Adenocarcinoma of the Endometrium.- 47. Solitary Lung Lesion 9 Months
After the Diagnosis of Endometrial Cancer.- 48. Cervical Cancer, Stage IIB,
Squamous Cell.- 49. Locally Advanced Cervical Cancer in a Young Woman.-
50. Advanced Cervical Cancer with Bilateral Ureteral Obstruction.-
51. Metastatic Recurrent Cervical Squamous Cell Carcinoma.- 52. Pelvic Mass
Recurrence Following Surgery and Radiation for Locally Advanced Cervical
Cancer.- 53. Central Recurrence of Advanced Cervical Cancer 10 Months
Following Surgery and Radiation Therapy.- 54. Locally Advanced Cervical
Cancer in a Woman Who Is HIV-Positive.- 55. Locally Advanced Cervical Cancer
in a Woman with a History of Scleroderma Who Refuses Blood Products.-
56. Small-Cell Carcinoma of the Cervix.- 57. Cervical Cancer, Adenosquamous (
Stage IB, Post-Simple Hysterectomy).- 58. Cervical Cancer, Adenosquamous
(Stage IB/Surgical Stage IIIB).- 59. Cervical Cancer, Squamous Cell, IB, 3-
to 5-mm Invasion.- 60. Cervical Cancer, Adenocarcinoma Microinvasive.-
61. Cervical Cancer, Squamous Cell, Stage IIA.- 62. Cervical Dysplasia;
Persistent CIN1.- 63. Ovarian Cancer, Epithelial (Early Disease, Unstaged). 
Jae-Weon Kim, M.D., Ph.D., Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.Aikou Okamoto, M.D., Ph.D., Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo, Japan.

Jianliu Wang, M.D., Ph.D., Department of Obstetrics and Gynecology, Peking University Peoples Hospital, Beijing, China.